Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Inventory Average (2016 - 2025)

Protalix BioTherapeutics has reported Inventory Average over the past 14 years, most recently at $23.5 million for Q4 2025.

  • Quarterly results put Inventory Average at $23.5 million for Q4 2025, up 22.22% from a year ago — trailing twelve months through Dec 2025 was $23.5 million (up 22.22% YoY), and the annual figure for FY2025 was $23.5 million, up 16.59%.
  • Inventory Average for Q4 2025 was $23.5 million at Protalix BioTherapeutics, up from $21.2 million in the prior quarter.
  • Over the last five years, Inventory Average for PLX hit a ceiling of $23.5 million in Q4 2025 and a floor of $13.5 million in Q1 2021.
  • Median Inventory Average over the past 5 years was $19.1 million (2024), compared with a mean of $18.4 million.
  • Biggest five-year swings in Inventory Average: soared 53.02% in 2021 and later fell 8.01% in 2024.
  • Protalix BioTherapeutics' Inventory Average stood at $16.3 million in 2021, then decreased by 4.03% to $15.7 million in 2022, then increased by 29.53% to $20.3 million in 2023, then fell by 5.38% to $19.2 million in 2024, then increased by 22.22% to $23.5 million in 2025.
  • The last three reported values for Inventory Average were $23.5 million (Q4 2025), $21.2 million (Q3 2025), and $20.3 million (Q2 2025) per Business Quant data.